EXHIBIT 23.2
Published on July 31, 2024
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-4) and related Prospectus of
Acasti Pharma Inc. and to the incorporation by reference therein of our report dated June 23, 2023, except for the effects of the reverse stock split described in Note 1, as to which the date is June 21, 2024, with respect to the consolidated
financial statements of Acasti Pharma Inc. included in its Annual Report (Form 10-K) for the year ended March 31, 2024 filed with the Securities and Exchange
Commission.
/s/ Ernst & Young LLP
Montréal, Canada
July 31, 2024